In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Pulmatrix, Inc.. Trade Record

NASDAQ:PULM Pulmatrix, Inc. stock gains 14.37% Exit Mar 20, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart PULM Mar 7, 2019, priceSeries
About Pulmatrix, Inc.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF). It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease. The company has an alliance with Celdara to develop an inhaled biologic to treat IPF. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
87.76
Entry Date
Mar 7, 2019
Entry Price
1.27
Sell Date
Mar 20, 2019
Sell Price
1.45
Net Gain
14.37%
Hold Time
9 Trading Days